AstraZeneca in AI Collaboration with Immunai to Inform Cancer Drug Trials
AstraZeneca has announced a significant collaboration with Immunai Inc., a biotechnology firm based in New York, to leverage Immunai’s advanced AI model of the immune system. The collaboration aims to enhance clinical decision-making processes in cancer drug trials. AstraZeneca will pay $18 million to Immunai for the use of their AI platform, which will help in making informed decisions regarding dose selection and biomarker identification. This partnership is expected to significantly improve the efficiency and accuracy of cancer drug trials, potentially leading to more effective treatments for patients. The collaboration underscores the growing importance of artificial intelligence in the pharmaceutical industry, particularly in the complex field of cancer research.
